-
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)
YOKOHAMA, Japan, June 24, 2026 /PRNewswire/ — REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in…
-
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 June 07, 2026 19:30 ET | Source: LENZ Therapeutics, Inc. SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine…
-
BBBS & Israel's Foresight Awarded USD 5 Million to Build & Commercialize Rugged Autonomous Drones for Hazardous Industrial Environments
Big Bang Boom Solutions Pvt. Ltd. (BBBS), a leading Indian DeepTech startup, today announced the formal approval of a $5 million joint research, development, and commercialization project with Israel-based Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX). The project, funded under the India-Israel Industrial R&D and Technological Innovation Fund (I4F), will focus on developing rugged…
-
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
June 05, 2026 20:13 ET | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash,…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
